Skip to main navigation
Skip to Content
logo
  • Overview
  • Stock Information
    • Stock Quote and Chart
    • Historical Price Lookup
    • IRS Form 8937
  • SEC Filings
  • Corporate Governance
    • Governance Documents
    • Management Team
    • Board of Directors
    • Committee Composition
    • Investor FAQs
  • Company
    • Press Releases
    • Events & Presentations
    • Pipeline
  • Contact Us
  • ImmunityBio.com

SEC Filing

SEC Filing Details

Document Details

Form
SCHEDULE 13D/A
Filing Date
Aug 6, 2026
Document Date
Aug 6, 2026
Form Description
SCHEDULE 13D/A - Description
Filing Group
Other
Company
ImmunityBio, Inc.
Issuer
IMMUNITYBIO, INC.

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS

IR Tools

Print Page
RSS Feeds
Email Alerts
logo

NantKwest

Visit ImmunityBio.com

Quicklinks

  • Pipeline
  • Careers
  • News and Events
  • Investors
  • Contact

Follow Us

  •  facebook
  •  twitter
  •  linkedin

Legal

  • Privacy Policy
  • Terms of Use
  • Health Data Privacy Policy
  • Patent Notice
  • Social Media Community Guidelines
  • Your Privacy Choices
© 2026 ImmunityBio, Inc. All Rights Reserved.
A member of the NantWorks ecosystem of companies

'ImmunityBio', 'ImmunityBio Care', 'Anktiva', 'ThAnktiva', 'haNK', 'taNK', 'ceNK', 'NK-92', 'Nant Cancer Vaccine', 'NANT 001', 'NANT XL', 'NANT 001 and Design', 'QUILT', 'Outsmart Your Disease', 'Smart Therapies for Difficult Diseases', 'Nantkwest', 'VivaBioCell', and 'Infacell' are trademarks or registered trademarks of ImmunityBio, Inc., its subsidiaries and affiliates.

The Natural Killer Cell platform consists of investigational agents that are restricted by federal law to investigational use only.

The Natural Killer Cell platform is being investigated in multiple clinical trials across tumor sites.

The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.